Effects of Shakuyaku-kanzo-to on Muscle Pain from Combination Chemotherapy with Paclitaxel and Carboplatin

Yamamoto, Kaichirô; Hoshiai, Hiroshi; Noda, Kiichiro

doi:10.1006/gyno.2001.6168

Cited by 47 publications

(34 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The daily extract dose of SKT in human is 2.5 g, which is derived from 6 g of G. radix and 6 g of P. radix. Clinical studies have shown that SKT induces a rapid and clinically significant improvement in muscle cramps arising from different causes, including liver cirrhosis (Kumada et al, 1999), hemodialysis (Hinoshita et al, 2003), and chemotherapy-induced myalgia and arthralgia (Yamamoto et al, 2001;Yoshida et al, 2009). Basic pharmacological studies have shown that SKT promotes intestinal smooth muscle relaxation via significant anticholinergic and phosphodiesterase 3 inhibitory actions (Satoh and Tsuro, 2011), suppresses neuromuscular transmission via intracellular Ca 2 þ mobilization (Dezaki et al, 1995), and alleviates pain associated with diabetic peripheral neuropathy via activation of spinal a 2 -adrenoceptors (Omiya et al, 2005;Lee et al, 2011).…”

Section: Introductionmentioning

confidence: 98%

Antispasmodic effect of shakuyakukanzoto extract on experimental muscle cramps in vivo: Role of the active constituents of Glycyrrhizae radix

Lee

Omiya

Yuzurihara

et al. 2013

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

Antispasmodic effect of shakuyakukanzoto extract on experimental muscle cramps in vivo: Role of the active constituents of Glycyrrhizae radix

Lee

Omiya

Yuzurihara

et al. 2013

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…In the treatment of muscle cramps, central or peripheral muscle relaxants are commonly used; however, their therapeutic effects are not always sufficient, and these agents cause side effects such as hepatopathy, weakness, and thirst. Shakuyakukanzoto markedly improves muscle cramps and pain without side effects (4,5); therefore, this Kampo medicine may be clinically useful. In contrast to these observations, it has been reported that shakuyakukanzoto does not show any antinociceptive activitiy in response to noxious stimuli in normal experimental animals (6).…”

Section: Introductionmentioning

confidence: 98%

Antinociceptive Effect of Shakuyakukanzoto, a Kampo Medicine, in Diabetic Mice

et al. 2005

View full text Add to dashboard Cite

Abstract. In this study, the antinociceptive effect of shakuyakukanzoto was investigated using streptozotocin-induced diabetic mice to certify its analgesic effect on diabetic patients. Shakuyakukanzoto (0.5 and 1.0 g / kg, p.o.) significantly increased the nociceptive threshold in diabetic mice. The antinociceptive activity of shakuyakukanzoto in diabetic mice was not antagonized by β-funaltrexamine, naltrindole, or nor-binaltorphimine. The increased antinociceptive activity of (1.0 g / kg, p.o.) in diabetic mice was abolished by yohimbine (15 µg, i.t.), but not by (1 µg, i.t.), methysergide (15 µg, i.t.), or MDL-72222 (15 µg, i.t.). In shakuyakukanzoto diabetic mice treated with 6-hydroxydopamine (20 µg, i.t.) chemically lesioned noradrenergic pathways, shakuyakukanzoto (1.0 g / kg, p.o.) failed to exhibit an antinociceptive effect. Furthermore, the antinociceptive activity induced by norepinephrine (0.06 -2 µg, i.t.) was markedly more potent in diabetic mice than in non-diabetic mice at the same dose. These results suggest that the antinociceptive effect of shakuyakukanzoto in diabetic mice is not mediated by the opioid systems and that this effect appears via selective activation of the spinal descending inhibitory α 2 -adrenergic systems without activating the serotonergic systems. The spinal α 2 -adrenoceptor-mediated analgesic mechanism was enhanced in diabetic mice, suggesting that shakuyakukanzoto exhibits its effect by activating the descending noradrenergic neurons.

show abstract

“…Based on this concept, several kinds of Kampo formula have been widely used for palliative care including cancer associated symptoms and adverse effect of chemotherapy in Japan 5) . SKT, a Kampo formulation with anticholinergic and prostaglandin inhibitory effect has been reported to be effective in reducing muscle pain, muscle spasms, joint pain and numbness 2,[6][7][8] . So, we first tried SKT for the treatment for the muscle cramps induced by S-1 administration.…”

Section: Discussionmentioning

confidence: 99%

A case of unresectable pancreatic cancer successfully treated with Gosha-jinki-gan for muscle cramps related to administration of S-1

Arakawa

Nitta

Ajihara

et al. 2017

Ann. Cancer Res. Therap.

View full text Add to dashboard Cite

We experienced a pancreatic cancer patient whose muscle cramp arose by using S-1 was improved by the administration of a Kampo formulation Goshajinkigan (GJG).Eighty-year-old female was diagnosed as having unresectable pancreatic cancer and then chemotherapy with S-1 and gemcitabine was initiated. After 4th course, gemcitabine had been discontinued by the toxicity, and then single administration for two weeks of a dose of 80 mg of S-1 was continued every three weeks. She often experienced muscle cramp at low legs, and she visited the emergency room with complaint of gait disturbance due to worse of muscle cramps. Her biochemical study showed almost normal electrolytes levels. Then a Kampo formulation Shakuyaku-kanzo-to (SKT), which was thought to be rapid-acting for these symptoms, was administered because of her sustained marked symptoms. No effect of SKT on these symptoms was observed; therefore, GJG was selected by Kampo medicine physician in combination with her complaints and body status. The administration of GJG was started 2.5 g once a day and then dose escalation was scheduled because it might induce gastrointestinal disorders. Since dose was escalated 5 g twice a day 2 weeks after initiation, incidence of muscle cramp was reduced three times a week. After 7 weeks, symptoms were disappeared. At this moment, she can continue the chemotherapy with S-1 under control of adverse event by the administration of 5 g of GJG twice a day.

show abstract

Effects of Shakuyaku-kanzo-to on Muscle Pain from Combination Chemotherapy with Paclitaxel and Carboplatin

Cited by 47 publications

References 2 publications

Antispasmodic effect of shakuyakukanzoto extract on experimental muscle cramps in vivo: Role of the active constituents of Glycyrrhizae radix

Antispasmodic effect of shakuyakukanzoto extract on experimental muscle cramps in vivo: Role of the active constituents of Glycyrrhizae radix

Antinociceptive Effect of Shakuyakukanzoto, a Kampo Medicine, in Diabetic Mice

A case of unresectable pancreatic cancer successfully treated with Gosha-jinki-gan for muscle cramps related to administration of S-1

Contact Info

Product

Resources

About